GLOW and KLOW Peptide Blends: What Is in Them

What is in GLOW and in KLOW?

GLOW and KLOW are product names, not drug names. Sellers describe GLOW as an injectable blend of three peptides, GHK-Cu, BPC-157 and TB-500, marketed mainly for skin and recovery, and describe KLOW as the same three with KPV added. That is a marketing description read on seller product pages in September 2026. No pharmacopeia, regulator or published study defines either name, so the ratio, the amount of each peptide and the other ingredients can differ from one product to the next.

The names have no scientific literature of their own. As of September 2026, none of the phrases GLOW peptide, KLOW peptide, GLOW blend or KLOW blend appears in any PubMed record ^[9]. ClinicalTrials.gov returns no study of either blend and no registered study that combines any two of the four peptides ^[10].

What is the US status of each component?

No component is an approved drug, and the four do not share one legal position. Three of them, BPC-157, TB-500 and KPV, were removed from Category 2 of FDA's interim 503A bulks list in April 2026 without being added to Category 1, and in July 2026 the Pharmacy Compounding Advisory Committee voted to recommend each for the 503A list ^{[6, 7, 8]}. That vote is advisory; FDA has issued no final rule, so none of the three may yet be lawfully compounded. GHK-Cu followed a different path: FDA's list document places GHK-Cu in Category 1 except for injectable routes, and the injectable route sits on no list ^[1]. A blend sold for injection therefore contains at least one ingredient, injectable GHK-Cu, with no lawful compounding route at all.

What has been tested in people?

Nothing that matches the product. For the combination, the six PubMed records that name GHK-Cu, BPC-157 and TB-500 together are all 2026 review articles on peptide therapies, and BPC-157 and KPV never appear together in an indexed record ^[9]. PubMed indexes no trial of any combination of the four ^[9].

Component by component, the record is thin. BPC-157 has no record under either trial publication type across four of its names ^[11] and three uncontrolled human reports from one practice, with 16, 12 and 2 participants ^{[12, 13, 14]}. TB-500's single trial-type record is a tuberculosis study matched on the letters TB ^[15]; a first randomized trial of the fragment was registered in 2026 and is still recruiting ^[16]. KPV returns no trial of any kind ^{[9, 17]}. GHK-Cu has two human trials, both applying it to skin ^[18]; the topical versus injectable review reads them in full.

The trial registry shows studies under way for single components, including a phase 2 trial of BPC-157 in hamstring strain and a phase 2 trial of a topical GHK-Cu gel, and none has posted results ^[10]. The BPC-157 human trial record and the TB-500 versus thymosin beta-4 review set out what each molecule's human record does and does not contain.

Why is a blend not the sum of its evidence?

Even if each peptide had a strong record alone, a combination would need its own. Four peptides in one vial are a new formulation, and a formulation is judged on its own stability, purity and behavior in the body. A 2026 pharmaceutics review of BPC-157 alone describes a molecule whose human pharmacokinetics remain largely uncharacterized and which has no approved formulation or validated dosing regimen ^[19]. Mixing it with three other peptides adds questions no single-peptide study answers: whether each peptide remains stable in the same solution, and whether one alters how another behaves.

A blend also defeats attribution. When a person reports an effect, good or bad, after injecting four peptides at once, no one can say which peptide caused it, or whether the combination did. The one dataset that could separate them, a controlled trial that tests each component and the mixture, does not exist ^{[9, 10]}.

Content is a further unknown. A laboratory analysis of products sold online as TB-500 found that their contents did not consistently match their labels ^[20], and a 2026 review of unregulated injectable peptides lists contamination, manufacturing impurities and inaccurate dosing among their risks ^[21]. A research-use-only blend carries that uncertainty for every ingredient it contains.

What did FDA say about these substances?

The concerns are about the molecules, not about any seller. FDA placed BPC-157 in Category 2 in September 2023, citing immunogenicity risk and impurity questions ^[22], and its safety-risk page, current as of April 22, 2026, states that compounded BPC-157 may pose a risk of immunogenicity for certain routes and may have complexities with peptide-related impurities and API characterization, meaning confirming what the active ingredient is and how pure it is ^[3]. For TB-500 it cites the potential for aggregation and impurities and states that it has identified no human exposure data ^[4]; for KPV it states that it has identified no human exposure data by any route ^[5]; for injectable GHK-Cu it cites immunogenicity from aggregation and impurities and limited human data ^[2].

The April 2026 removal of BPC-157, TB-500 and KPV from Category 2 ended an explicit prohibition and conferred no authorization; what Category 2 removal does not mean explains the difference. The July 2026 votes were reported as 8–6 with one abstention for each of the three, by two law-firm accounts that agree, and FDA itself has published no vote record for that meeting ^{[6, 7, 8]}; the July 2026 vote ledger prints the figures with their provenance. GHK-Cu was not on that agenda.

How does topical GHK-Cu differ from an injected blend?

They are different products under different law. A GHK-Cu cream or serum sold to improve appearance is a cosmetic, which does not need FDA premarket approval; a product intended to affect the structure or function of the body is a drug ^[23]. GHK-Cu for non-injectable routes sits in Category 1, while the injectable route sits on no list ^[1]. Its two human trials both applied it to skin ^[18], so the topical record cannot vouch for an injection, and it says nothing about BPC-157, TB-500 or KPV. The topical versus injectable review covers that split in detail.

What are the side effects of GLOW and KLOW?

They are not known. No study has measured the side effects of either blend, and none of the four components has a controlled human safety record for the way the blends are used. The uncontrolled BPC-157 pilots, covering 14 people across two reports, recorded no adverse events, but reports that small cannot detect an uncommon harm ^{[13, 14]}.

What is known is the list of open questions. FDA's concerns about immune reactions and impurities apply to each injected component ^{[2, 3, 4]}. Reviewers add theoretical risks from the biology, such as unwanted blood vessel growth, and from product quality, such as contamination and inaccurate dosing ^[21]. A 2026 review of unapproved peptides in sports medicine, covering GHK-Cu, BPC-157 and TB-500, concludes that rigorous human safety data are scarce and that there is potential for serious harm ^[24]. Each component's monograph, linked in the table above, carries the full record.

Elsewhere in this index